
Timestamp, Slide Content Summary
00:00 - 01:05,Title and Introduction: Overview of NICE NG238 and AAC Lipid Pathways; speaker bio for Prof. Narendra Kumar.
01:06 - 01:32,"Session Objectives: Risk Assessment, Treatment Optimization (Statins/Newer Agents), and Lifestyle Adherence."
01:33 - 03:15,Evidence-Based Remission: Concepts of reversing chronic conditions like T2D through intensive lifestyle/medical intervention.
03:16 - 05:01,The Twin Cycle Hypothesis: How liver/pancreatic fat drives metabolic disease and the global health economic context of lipid drugs.
05:02 - 07:45,QRISK3 and Non-Fasting Lipids: The shift toward non-fasting blood tests and the specific limitations/underestimations of QRISK3.
07:46 - 10:12,"High-Risk Special Groups: Identifying patients (T1D, CKD, Clinical CVD) who bypass QRISK scoring for immediate treatment." 10:13 - 12:30,"Life-Course Risk: The ""Area Under the Curve"" concept—cumulative LDL exposure over decades vs. late-life intervention."
12:31 - 15:55,"Familial Hypercholesterolaemia (FH): Identifying FH (TC 7.5, LDL 4.9) and the importance of Simon Broome criteria and cascade testing." 15:56 - 18:20,First-Line Statin Therapy: Dosing standards (Atorvastatin 20mg for Primary vs. 80mg for Secondary Prevention).
18:21 - 21:10,"Baseline Diagnostics: Essential pre-treatment checks: Lipid profile, ALT/AST, eGFR, HbA1c, and CK (if symptomatic)."
21:11 - 25:00,The 40% Non-HDL Goal: Using Non-HDL as the primary metric for success and the logic behind the 3-month follow-up.
25:01 - 28:30,"Statin Intolerance Management: Addressing the Nocebo effect; protocols for ""Statin Challenges"" and switching to Rosuvastatin."
28:31 - 32:15,Ezetimibe (Second-Line): Mechanism of blocking gut absorption and achieving an additional 15-20% LDL reduction.
32:16 - 36:50,Bempedoic Acid (Nilemdo): A pro-drug activated in the liver to avoid muscle symptoms (SAMS) for intolerant patients. 36:51 - 42:29,"The AAC Escalation Hierarchy: Flowchart of adding Ezetimibe, Bempedoic Acid, and then moving to injectable therapies."
42:30 - 49:20,"Inclisiran (siRNA) Overview: The ""twice-yearly"" injection mechanism and the logistics of nurse-led community administration."
49:21 - 53:45,NICE TA733 Eligibility: Criteria for Inclisiran: Secondary prevention patients with persistent LDL 2.6 mmol/L or higher.
53:46 - 57:10,PCSK9 Inhibitor MABs: Review of Alirocumab/Evolocumab for very high-risk and FH populations.
57:11 - 61:30,The Legacy Effect: Data on the 22% reduction in vascular events per 1 mmol/L LDL drop.
61:31 - 65:00,Safety and Side Effects: Managing injection site reactions and confirming lack of liver/muscle toxicity for new agents.
65:01 - 72:15,"Addressing Clinical Inertia: The necessity of rapid combination therapy rather than ""wait and see"" monitoring."
72:16 - 78:40,"Q&A Session: Discussion on practical implementation in primary care, funding, and the ""primary care playbook"" checklist."
78:41 - 81:16,Summary and Closing: Final takeaways on bridging the gap between guidelines and patient adherence. Join this channel to get access to perks:
If you feel your current approach to cholesterol is “good enough,” but not truly confident or up to date, this diploma is designed for you. You will move from memorising targets to understanding the “why” behind every decision, so your management becomes faster, safer, and more consistent in real clinical practice.
What you will be able to do after this diploma
Rapidly assess cardiovascular risk and decide who truly needs treatment now vs later, avoiding both over- and under-treatment.
Choose and titrate statins and non-statin therapies using current, evidence-based algorithms, instead of guesswork.
Handle “difficult” scenarios: statin intolerance, polypharmacy, complex comorbidities, and older or frail patients.
Explain risks and benefits to patients in clear language that improves adherence and reduces complaints.
Confidently manage secondary prevention in patients with established ASCVD, diabetes, CKD, and familial hypercholesterolaemia.
Integrate lifestyle, pharmacology, and follow-up planning into one coherent, repeatable approach for every patient.
Who this diploma is for
Clinicians who worry about “missing something” in lipid results or guideline changes.
Doctors, trainees, pharmacists, and allied professionals who want a clear, practical system rather than dense theory.
Busy practitioners who want to stop re-reading guidelines before every difficult case.
How the course keeps you engaged
Short, focused lessons that target one decision at a time, so you always feel a small “win” and clear progress.
Realistic clinical cases that force you to think, decide, and then see the evidence behind the answer.
Checklists, simple frameworks, and “if/then” patterns you can apply on the ward, in clinic, or in primary care.
By the end of this diploma, you will have a structured, evidence-based way to manage cholesterol that you can trust under pressure, even in complex patients. Instead of hoping your decision is correct, you will know exactly why you chose each target, drug, and follow-up plan.